Drugs

What the Abortion Pill Ruling Means for FDA's Authority

By Alice Park

All Types of Hormonal Birth Control Share a Slightly Increased Risk of Breast Cancer

By Haley Weiss

Sanofi Becomes Third Insulin Producer to Cut Prices

By Ilena Peng/Bloomberg

Psychedelics Could Revolutionize Couples Therapy

By Jamie Ducharme
More in Drugs

The VA Will Pay for Some to Get New Alzheimer’s Drug

It's a move toward broader coverage of the controversial drug category.

By John Tozzi and Robert Langreth/Bloomberg

FDA Approves a New Nasal Spray to Treat Migraines

The drug, zavegepant (brand name: Zavzpret), is the first of its type available in a nasal spray.

By Alice Park

Is the Marijuana Legalization Movement in Trouble?

Voters in Oklahoma resoundingly rejected a legalization measure on the ballot Tuesday—following rejections in 2022 in three other states

By Tara Law

Only Drug to Prevent Premature Births Will Be Pulled from U.S. Market

While the drug Makena won accelerated FDA approval in 2011, a study found it didn’t work better than older drugs.

By Michelle Fay Cortez/Bloomberg

How the Other Insulin Makers Are Responding to Eli Lilly’s Price Cap

Health policy experts say Eli Lilly's competitors are now facing increasing pressure to respond.

By Nik Popli

Ozempic's Popularity Is Triggering People with Eating Disorders

'I don't need to read more gory details.'

By Jamie Ducharme

FDA Panel Backs GSK’s RSV Vaccine for Older People

The drugmaker is racing against Pfizer Inc. to bring to market the first vaccine for RSV.

By Lisa Pham and Tanaz Meghjani/Bloomberg

A New Alzheimer's Drug Gave Patients Hope. Millions Can't Get It

An unusual Medicare reimbursement policy means that promising new drugs for Alzheimer's, like Leqembi, are out of reach for most patients.

By Alice Park

Psychedelics May Be Part of U.S. Medicine Sooner Than You Think

Australian psychiatrists will soon be able to prescribe MDMA and psilocybin. The U.S. may not be too far behind.

By Jamie Ducharme

Eli Lilly's Alzheimer’s Drug Donanemab Fails to Get Early FDA Approval

In an unexpected setback for the drugmaker, Eli Lilly & Co.’s bid for accelerated approval of donanemab was rejected by U.S. regulators.

By Robert Langreth and Nacha Cattan/Bloomberg

FDA Approves Lecanemab, a New Alzheimer’s Drug

The drug could be the most effective yet to treat Alzheimer’s, but caution is warranted.

By Alice Park

Colorado Votes to Decriminalize Psychedelics

Colorado voters have approved the broadest psychedelic legalization in the U.S.

By Tara Law

Adderall Shortage Expected to Continue for Months in the U.S.

Teva Pharmaceutical Industries’ Adderall shortage is expected to last through March—which is longer than anticipated.

By Ike Swetlitz/Bloomberg

Why Overdose Deaths Have Increased

Opioid prescriptions have dropped in every state over the last decade, but the effort to prevent overdose deaths is an abject failure

By Tara Law

What to Know About ‘Rainbow Fentanyl’

It's dangerous for teens, but experts say there are greater risks

By Tara Law

Taking Psychedelics Could Make People Less Afraid of Dying

New research found that psychedelics and near-death experiences both reduced anxiety about death

By Tara Law
1234...31
More from TIME
More From TIME